Status:

UNKNOWN

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

Lead Sponsor:

ZymoGenetics

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

Hepatitis C, Chronic

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to evaluate the safety and antiviral effects of several different doses ...

Detailed Description

PEG-rIL-29 (also known as PEG-interferon lambda) is a unique Type III interferon molecule that has demonstrated antiviral activity when administered weekly for 4 weeks to treatment-relapsed and treatm...

Eligibility Criteria

Inclusion

  • No prior therapy for chronic HCV, other than up to 2 weeks of single-agent therapy with a direct-acting antiviral agent, including but not limited to, a protease or polymerase inhibitor
  • HCV genotype 1, 2, 3, or 4
  • HCV RNA ≥100,000 IU/mL
  • ALT and AST ≤5.0 × ULN
  • Documented absence of cirrhosis
  • Able to comprehend the investigational nature of this study and sign an informed consent form

Exclusion

  • Mixed genotype HCV infection
  • Current or prior history of decompensated liver disease
  • Received any investigational drug, including a direct-acting antiviral agent, within 60 days prior to receiving study drug
  • Positive test for hepatitis B surface antigen, human immunodeficiency virus (HIV)-1, or HIV2 antibody at screening
  • Active substance abuse, such as alcohol, or inhaled or injected drugs, within 6 months
  • Additional inclusion and exclusion criteria are specified in the protocol.

Key Trial Info

Start Date :

May 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2012

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT01001754

Start Date

May 1 2010

End Date

May 1 2012

Last Update

December 5 2011

Active Locations (79)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 20 (79 locations)

1

Beverly Hills, California, United States

2

Coronado, California, United States, 92118

3

La Jolla, California, United States

4

Palm Springs, California, United States, 92262